Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors
- PMID: 35461743
- DOI: 10.1053/j.ajkd.2022.02.012
Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors
Erratum in
-
Erratum Regarding "Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors" (Am J Kidney Dis. 2022;80[2]:159-160).Am J Kidney Dis. 2022 Nov;80(5):690. doi: 10.1053/j.ajkd.2022.09.001. Am J Kidney Dis. 2022. PMID: 36273832 No abstract available.
Comment on
-
Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.Am J Kidney Dis. 2022 Aug;80(2):164-173.e1. doi: 10.1053/j.ajkd.2022.01.002. Epub 2022 Jan 25. Am J Kidney Dis. 2022. PMID: 35085685
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
